Browsing Tag
Bofanglutide
4 posts
Lupin (NSE: LUPIN) signs licensing deal with Gan & Lee for Bofanglutide GLP-1 in India
Lupin signs exclusive India deal for Bofanglutide, a novel fortnightly GLP-1. Find out how it could reshape the obesity and diabetes market in 2026.
Gan & Lee Pharmaceuticals reveals competitive Phase 2 results for bofanglutide and GZR4 at ADA 2025 sessions
Gan & Lee Pharmaceuticals presented strong Phase 2 results for bofanglutide and GZR4 in type 2 diabetes, advancing its long-acting diabetes pipeline.
How are AI models and new clinical treatments reshaping diabetes care after the 2025 ADA conference?
ADA 2025 highlights AI diagnostics and breakthrough injectables in diabetes care, signaling early detection and superior glycemic control in clinical trials.
Gan & Lee Pharmaceuticals begins US Phase 2 trial of bofanglutide for obesity and weight management
Gan & Lee Pharmaceuticals (Shanghai Stock Exchange: 603087) has initiated its Phase 2 clinical trial of bofanglutide (GZR18)…